The reduced cardiac functionality in Anxa1−/− mice after MI could be restored by AnxA1 administration, overcoming compromised release of proangiogenic mediator vascular endothelial growth factor (VEGF) from cardiac macrophages, and markedly improving neovascularization and cardiac repair [53]. This evidence concerns the gene ANXA1 and myocardial infarction.